Skip to Main Content

Advertisement

Skip Nav Destination

Editor's Corner


Clinical Trial Design Fails Too Many Patients

September 2022

Matthew Matasar, MD

The history of clinical trials in general, and more specifically in hematology and lymphoma, is one that both inspires and disappoints. The breadth and pace of innovation is breathtaking and gives hope to doctors and patients alike, but how well does the clinical research enterprise serve the patients for whom we intend it?

Pulling Back the Curtain: Thomas R. Chauncey, MD, PhD

September 2022

In this edition, Dr. Chauncey discusses his winding road to medicine and the joys and challenges of clinical care and trial work.

Cardiovascular Disease and Myeloproliferative Neoplasms

September 2022

The association between MPNs and an increased risk of both thrombotic and hemorrhagic complications has been recognized for some time, and cardiovascular events contribute significantly to morbidity and mortality in patients with MPNs.

AlloHCT Outcomes Improved in Adults With ALL

September 2022

These study results confirm the maturity of the alloHCT method and its role as a curative treatment for ALL in adults. This is especially the case since inotuzumab, ozogamicin, and blinatumomab were approved in 2018, and tisaglenlecleucel was approved in 2019 in Japan for the treatment of relapsed/refractory ALL.

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement